Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
Portfolio Pulse from Vandana Singh
Creative Medical Technology Holdings Inc (NASDAQ:CELZ) saw its stock surge after receiving FDA authorization for CELZ-201, a therapy aimed at managing abnormal glucose tolerance and preventing Type 1 diabetes in high-risk individuals. This groundbreaking therapy represents a significant advancement in personalized medicine for diabetes management. Additionally, CELZ received Orphan Drug Designation for CELZ-101, ImmCelz, to prevent allograft rejection in pancreatic islet cell transplantation for Type 1 diabetes patients. CELZ shares rose 34.50% to $6.40.
March 07, 2024 | 6:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Creative Medical Technology Holdings Inc received FDA authorization for CELZ-201 to manage abnormal glucose tolerance and prevent Type 1 diabetes, and Orphan Drug Designation for CELZ-101, leading to a 34.50% increase in stock price to $6.40.
The FDA authorization for CELZ-201 and the Orphan Drug Designation for CELZ-101 are significant regulatory milestones for Creative Medical Technology Holdings Inc, indicating a strong potential for the company's therapies in diabetes management. These developments are likely to boost investor confidence and drive up the stock price in the short term, as evidenced by the 34.50% increase.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100